mianserin has been researched along with Basal Ganglia Diseases in 4 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighteen inpatients with treatment-resistant schizophrenia who had an acute psychotic exacerbation of the disorder received, in a double-blind design, 30 mg/day mianserin (n = 9) or placebo (n = 9) in conjunction with typical neuroleptics [haloperidol (n = 9) or perphenazine (n = 9)]." | 6.70 | Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. ( Aizenberg, D; Bodinger, L; Munitz, H; Shiloh, R; Valevski, A; Weizman, A; Zemishlany, Z, 2002) |
| "Eighteen inpatients with treatment-resistant schizophrenia who had an acute psychotic exacerbation of the disorder received, in a double-blind design, 30 mg/day mianserin (n = 9) or placebo (n = 9) in conjunction with typical neuroleptics [haloperidol (n = 9) or perphenazine (n = 9)]." | 2.70 | Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia. ( Aizenberg, D; Bodinger, L; Munitz, H; Shiloh, R; Valevski, A; Weizman, A; Zemishlany, Z, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, MY | 1 |
| Etminan, M | 1 |
| Procyshyn, RM | 1 |
| Kim, DD | 1 |
| Samii, A | 1 |
| Kezouh, A | 1 |
| Carleton, BC | 1 |
| Nagata, T | 1 |
| Shinagawa, S | 1 |
| Tagai, K | 1 |
| Nakayama, K | 1 |
| Robertson, VB | 1 |
| Wilson, MS | 1 |
| Shiloh, R | 1 |
| Zemishlany, Z | 1 |
| Aizenberg, D | 1 |
| Valevski, A | 1 |
| Bodinger, L | 1 |
| Munitz, H | 1 |
| Weizman, A | 1 |
1 trial available for mianserin and Basal Ganglia Diseases
| Article | Year |
|---|---|
Mianserin or placebo as adjuncts to typical antipsychotics in resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Resistance; Drug Ther | 2002 |
3 other studies available for mianserin and Basal Ganglia Diseases
| Article | Year |
|---|---|
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxeti | 2018 |
A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease.
Topics: Antidepressive Agents, Tricyclic; Basal Ganglia Diseases; Depressive Disorder; Female; Hallucination | 2013 |
Neurotensin receptor agonists and antagonists for schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Data Interpretation, Statistical; Humans; Mianserin; M | 2005 |